Considerations in the medical management of pregnancy in transplant recipients

被引:25
作者
Josephson, Michelle A.
McKay, Dianne B.
机构
[1] Univ Chicago Hosp, Chicago, IL 60637 USA
[2] Scripps Res Inst, La Jolla, CA USA
关键词
transplantation; pregnancy; immunosuppression;
D O I
10.1053/j.ackd.2007.01.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Pregnancy, although rare in the patient with end-stage renal disease, is not uncommon in the transplant recipient. Physicians taking care of transplant recipients must be able to inform patients about the potential risks of pregnancy in this setting. The patient and her partner must know that the risks associated with pregnancy increase with worsening kidney function and hypertension. Current consensus opinion is that pregnancy can be relatively safely undertaken by 1 year after transplant if the patient has had no rejections during the year, allograft function is adequate, there are no infections that could affect the fetus, the patient is not taking teratogenic medications, and immunosuppressive medication dosing is stable. Consideration must be given to immunosuppression during pregnancy both with respect to the specific agents as well as the level of dosing. None of the medications are FDA category A; all are B or higher. Part of planning for pregnancy should include an evaluation of immunosuppression medication and a plan to modify the regimen prior to conception if its use may be risky for the developing fetus. Rejection can occur during a kidney transplant, so maintaining adequate immunosuppression is important. Other issues that need to be managed when caring for a pregnant transplant patient include: potential for infection (urinary tract infections are very common), hypertension, and anemia. The type of delivery, posttransplant contraception, and breast-feeding also need to be addressed. (c) 2007 by the National Kidney Foundation, Inc.
引用
收藏
页码:156 / 167
页数:12
相关论文
共 66 条
  • [21] DAVISON JM, 1982, J REPROD MED, V27, P613
  • [22] EBPG Expert Group on Renal Transplantation, 2002, Nephrol Dial Transplant, V17 Suppl 4, P1
  • [23] TERATOGENIC EFFECTS OF AZATHIPRINE (IMURAN)
    GITHENS, JH
    ROSENKRANTZ, JG
    TUNNOCK, SM
    [J]. JOURNAL OF PEDIATRICS, 1965, 66 (05) : 959 - +
  • [24] Darbepoetin alfa treatment for post-renal transplantation anemia during pregnancy
    Goshorn, J
    Youell, TD
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (05) : E81 - E86
  • [25] Pregnancy under sirolimus-based immunosuppression
    Guardia, O
    Rial, MD
    Casadei, D
    [J]. TRANSPLANTATION, 2006, 81 (04) : 636 - 636
  • [26] GENDER EFFECTS IN PHARMACOKINETICS AND PHARMACODYNAMICS
    HARRIS, RZ
    BENET, LZ
    SCHWARTZ, JB
    [J]. DRUGS, 1995, 50 (02) : 222 - 239
  • [27] Herold M, 2001, J CLIN ONCOL, V19, P3439
  • [28] Pregnancy in renal transplant recipients
    Hou, S
    [J]. ADVANCES IN RENAL REPLACEMENT THERAPY, 2003, 10 (01): : 40 - 47
  • [29] Pregnancy in chronic renal insufficiency and end-stage renal disease
    Hou, S
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (02) : 235 - 252
  • [30] Pregnancy after liver transplantation under tacrolimus
    Jain, A
    Venkataramanan, R
    Fung, JJ
    Gartner, JC
    Lever, J
    Balan, V
    Warty, V
    Starzl, TE
    [J]. TRANSPLANTATION, 1997, 64 (04) : 559 - 565